Metered-dose intestinal oxygen delivery therapeutic - LPOXY Therapeutics
Alternative Names: LP-102 - LPOXY Therapeutics; Sidiprev - LPOXY Therapeutics; SIDIPREV™Latest Information Update: 09 Sep 2025
At a glance
- Originator LPOXY Therapeutics
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Colitis; Crohn's disease; Ulcerative colitis
Most Recent Events
- 03 Sep 2025 LPOXY Therapeutics announces intention to submit LPAD NDA application for antibiotic-induced C. difficile colitis (Prevention) in 2029 (LPOXY Therapeutics Pipeline, January 2025)
- 03 Sep 2025 LPOXY Therapeutics plans a registrational STOP-Cdiff trial for Colitis (Prevention) in Q3 2026
- 05 Feb 2025 Sidiprev - LPOXY Therapeutics is available for licensing as of 05 Feb 2025. https://www.lpoxy.com/company